Zubsolv® (buprenorphine and naloxone) sublingual tablet (CIII) is indicated for treatment of opioid dependence and should be used as part of a comprehensive treatment plan, which includes counseling and psychosocial support.
Abstral is a drug that provides fast and effective treatment of breakthrough pain in cancer patients. It is based on Orexo's sublingual tablet technology and the analgesic fentanyl.
Edluar is based on Orexo’s sublingual tablet technology and the active substance zolpidem and offers treatment for short-term insomnia. Zolpidem is a well-documented substance that has been used for a long time against insomnia. The Edluar tablet is placed under the tongue where it rapidly dissolves and the active substance is absorbed through the mucous membrane.
Orexo previously marketed Diabact® UBT, Heliprobe® System and IRIS™ through its subsidiary Kibion. The breath test and analytical instruments are used to diagnose the gastric ulcer bacterium Helicobacter pylori. Kibion was divested as of April 30, 2015. Read more in the press release.